8-K: Travere Therapeutics Reports Strong First Quarter 2024 Results Driven by FILSPARI Sales

Travere Therapeutics announced positive first quarter 2024 financial results, highlighted by increased FILSPARI sales and regulatory advancements.

Summary

• Travere Therapeutics reported a net product sales of $40.0 million for the first quarter of 2024, compared to $24.2 million for the same period in 2023.
• FILSPARI net product sales reached $19.8 million in Q1 2024, with a total of 1,963 patient start forms received since launch.
• The company's research and development expenses decreased to $49.4 million, down from $58.2 million in the same period last year.
• Selling, general, and administrative expenses also saw a reduction, totaling $64.2 million compared to $66.0 million in Q1 2023.
• A $65 million IPR&D milestone expense was recognized due to the first patient dosed in the HARMONY Study for pegtibatinase.
• The company's net loss for the quarter was $136.1 million, or $1.76 per basic share, compared to a net loss of $86.3 million, or $1.27 per basic share for the same period in 2023.
• As of March 31, 2024, Travere had $441.0 million in cash, cash equivalents, and marketable securities.
• The FDA granted Priority Review for the sNDA to convert FILSPARI's accelerated approval to full approval, with a PDUFA target action date of September 5, 2024.
• The European Commission granted conditional marketing authorization for FILSPARI, with the first European launch anticipated in the second half of 2024.
• The first patients were dosed in the pivotal Phase 3 HARMONY Study of pegtibatinase, with topline data expected in 2026.

Sentiment

Score: 6

Explanation: The document presents a mixed picture. While there are positive developments such as strong FILSPARI sales and regulatory progress, the increased net loss and milestone expenses temper the overall sentiment. The company's future outlook is positive, but there are risks associated with regulatory approvals and clinical trials.

Positives

• FILSPARI sales are showing strong growth, with $19.8 million in net product sales in Q1 2024.
• The company received 511 new patient start forms for FILSPARI in Q1 2024, indicating strong demand.
• FILSPARI received Priority Review from the FDA for full approval, with a target action date of September 5, 2024.
• FILSPARI received conditional marketing authorization in Europe, with the first launch expected in the second half of 2024.
• The first patients were dosed in the pivotal Phase 3 HARMONY Study of pegtibatinase, a key milestone for the HCU program.
• The company has a strong cash position with $441.0 million in cash, cash equivalents, and marketable securities.
• Total net product sales increased significantly to $40.0 million in Q1 2024, compared to $24.2 million in Q1 2023.
• Research and development expenses decreased to $49.4 million, down from $58.2 million in the same period last year.
• Selling, general, and administrative expenses also saw a reduction, totaling $64.2 million compared to $66.0 million in Q1 2023.

Negatives

• The company reported a net loss of $136.1 million for the first quarter of 2024, which is higher than the $86.3 million loss in the same period last year.
• The company recognized a $65 million IPR&D milestone expense due to the first patient dosed in the HARMONY Study of pegtibatinase.
• The company had non-recurring cash use of approximately $61 million related to the previously announced strategic restructuring, first quarter compensation expense, delivery of inventory and transfer of receivables related to the divestiture of the bile acid product portfolio.

Risks

• The company faces risks associated with the ongoing commercial launch of FILSPARI, including market acceptance and competition.
• There is no guarantee that regulators will grant full approval of sparsentan for IgAN or FSGS.
• The company faces risks related to the timing and potential outcome of clinical studies.
• The company may be unable to raise additional funding that may be required to complete development of its product candidates.
• The company is dependent on contractors for clinical drug supply and commercial manufacturing.
• The company faces risks associated with regulatory interactions and competitive products.
• Global and macroeconomic conditions, including health epidemics and pandemics, could disrupt clinical trials, commercialization activity, supply chain, and manufacturing operations.

Future Outlook

The company anticipates continued growth in 2024 and beyond, driven by FILSPARI sales and the advancement of its pipeline programs. They expect to receive a $17.5 million milestone payment from CSL Vifor upon conversion of the CMA to full approval, and an additional milestone payment in 2025 upon achievement of market access milestones in certain countries. The company also expects to pay a $5.8 million milestone to Ligand Pharmaceuticals in the second quarter of 2024.

Management Comments

• Eric Dube, Ph.D., president and chief executive officer of Travere Therapeutics, stated that the company is off to an excellent start to 2024, reporting new highs in both demand and revenue for FILSPARI.
• Eric Dube also expressed confidence in the company's ability to deliver significant growth in 2024 and beyond.
• Management noted they remain on track with other priorities to expand growth, including dosing the first patients with HCU in their pivotal program.

Industry Context

The announcement reflects a positive trend in the rare disease therapeutics market, with Travere's FILSPARI demonstrating strong commercial performance and regulatory progress. The conditional marketing authorization in Europe and the priority review in the US are significant steps in expanding the reach of this treatment for IgAN. The company's focus on rare diseases and its pipeline development aligns with the broader industry trend of addressing unmet medical needs in this space.

Comparison to Industry Standards

• Travere's FILSPARI launch is showing strong initial sales of $19.8 million in the first quarter, which is a positive sign compared to other rare disease drug launches.
• The company's R&D expenses decreased to $49.4 million, which is a positive trend compared to other biotech companies that often see increasing R&D costs.
• The company's cash position of $441.0 million is relatively strong compared to other companies of similar size in the biotech sector, providing a solid foundation for future growth.
• The company's net loss of $136.1 million is higher than the previous year, which is not uncommon for biotech companies in the development stage, but it is important to monitor this trend.
• The company's progress with the HARMONY study for pegtibatinase is a positive development, as it is a potential disease-modifying therapy for HCU, a rare disease with limited treatment options. This is comparable to other companies developing novel therapies for rare diseases.
• The company's engagement with regulators for sparsentan in FSGS is a positive step, but it is important to note that there is no guarantee of regulatory approval. This is a common risk for companies in the biotech sector.

Stakeholder Impact

• Shareholders may be encouraged by the strong FILSPARI sales and regulatory progress, but concerned about the increased net loss.
• Employees may be motivated by the company's positive momentum and pipeline advancements.
• Patients with IgAN and HCU may benefit from the availability of new treatment options.
• Customers may be satisfied with the company's commitment to developing and delivering life-changing therapies.
• Suppliers and creditors may be confident in the company's financial stability and growth prospects.

Next Steps

• The company will continue the commercial launch of FILSPARI.
• The company will work towards full FDA approval for FILSPARI, with a PDUFA target action date of September 5, 2024.
• The company will launch FILSPARI in European markets in the second half of 2024.
• The company will continue the Phase 3 HARMONY Study for pegtibatinase, with topline data expected in 2026.
• The company will engage with regulators to evaluate potential regulatory pathways for sparsentan in FSGS.

Key Dates

Keywords

FILSPARI, sparsentan, IgAN, pegtibatinase, HCU, FDA, European Commission, Priority Review, clinical trial, net product sales, financial results, biopharmaceutical